New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery

Tarek Y. El Ahmadieh, Salah G. Aoun, Marc R. Daou, Najib E. El Tecle, Rudy J. Rahme, Randall B. Graham, Joseph G. Adel, H. Hunt Batjer, Bernard R. Bendok

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A new generation of oral anticoagulants, namely direct thrombin inhibitors and factor Xa inhibitors, have recently been approved for clinical use in patients with atrial fibrillation. These novel families of drugs have been shown to have favorable efficacy and safety profiles in multiple clinical settings, particularly in the prevention of atrial fibrillation-related stroke, and are likely to become part of everyday practice, making a crossover to neurosurgical patients inevitable. Concern has risen regarding the complexity of managing intracranial and intraspinal hemorrhages related to these drugs. This review aims to provide an update on the most recent advances in oral anticoagulant drug therapy from a neurosurgeon's perspective. We discuss current evidence for the use of these novel agents, their limitations, existing methods of drug-level monitoring, and controversies related to anticoagulation reversal. We also discuss specific topics such as anticoagulation resumption after intracranial or intraspinal bleeding, perioperative anticoagulant administration, and the possibility of combination with tissue plasminogen activator in the setting of acute ischemic stroke. A special focus is given to the incidence of intracranial and intraspinal hemorrhage associated with each drug.

Original languageEnglish (US)
Pages (from-to)1350-1356
Number of pages7
JournalJournal of Clinical Neuroscience
Volume20
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Neurosurgery
Anticoagulants
Intracranial Hemorrhages
Stroke
Atrial Fibrillation
Pharmaceutical Preparations
Antithrombins
Drug Monitoring
Tissue Plasminogen Activator
Hemorrhage
Safety
Drug Therapy
Incidence

Keywords

  • Atrial fibrillation
  • Dabigatran
  • Intracranial hemorrhage
  • Neurosurgery
  • Oral anticoagulant
  • Reversal

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

El Ahmadieh, T. Y., Aoun, S. G., Daou, M. R., El Tecle, N. E., Rahme, R. J., Graham, R. B., ... Bendok, B. R. (2013). New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. Journal of Clinical Neuroscience, 20(10), 1350-1356. https://doi.org/10.1016/j.jocn.2013.05.009

New-generation oral anticoagulants for the prevention of stroke : Implications for neurosurgery. / El Ahmadieh, Tarek Y.; Aoun, Salah G.; Daou, Marc R.; El Tecle, Najib E.; Rahme, Rudy J.; Graham, Randall B.; Adel, Joseph G.; Hunt Batjer, H.; Bendok, Bernard R.

In: Journal of Clinical Neuroscience, Vol. 20, No. 10, 10.2013, p. 1350-1356.

Research output: Contribution to journalArticle

El Ahmadieh, TY, Aoun, SG, Daou, MR, El Tecle, NE, Rahme, RJ, Graham, RB, Adel, JG, Hunt Batjer, H & Bendok, BR 2013, 'New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery', Journal of Clinical Neuroscience, vol. 20, no. 10, pp. 1350-1356. https://doi.org/10.1016/j.jocn.2013.05.009
El Ahmadieh, Tarek Y. ; Aoun, Salah G. ; Daou, Marc R. ; El Tecle, Najib E. ; Rahme, Rudy J. ; Graham, Randall B. ; Adel, Joseph G. ; Hunt Batjer, H. ; Bendok, Bernard R. / New-generation oral anticoagulants for the prevention of stroke : Implications for neurosurgery. In: Journal of Clinical Neuroscience. 2013 ; Vol. 20, No. 10. pp. 1350-1356.
@article{be6cca61f74142a5b0e33c1e3fa343ce,
title = "New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery",
abstract = "A new generation of oral anticoagulants, namely direct thrombin inhibitors and factor Xa inhibitors, have recently been approved for clinical use in patients with atrial fibrillation. These novel families of drugs have been shown to have favorable efficacy and safety profiles in multiple clinical settings, particularly in the prevention of atrial fibrillation-related stroke, and are likely to become part of everyday practice, making a crossover to neurosurgical patients inevitable. Concern has risen regarding the complexity of managing intracranial and intraspinal hemorrhages related to these drugs. This review aims to provide an update on the most recent advances in oral anticoagulant drug therapy from a neurosurgeon's perspective. We discuss current evidence for the use of these novel agents, their limitations, existing methods of drug-level monitoring, and controversies related to anticoagulation reversal. We also discuss specific topics such as anticoagulation resumption after intracranial or intraspinal bleeding, perioperative anticoagulant administration, and the possibility of combination with tissue plasminogen activator in the setting of acute ischemic stroke. A special focus is given to the incidence of intracranial and intraspinal hemorrhage associated with each drug.",
keywords = "Atrial fibrillation, Dabigatran, Intracranial hemorrhage, Neurosurgery, Oral anticoagulant, Reversal",
author = "{El Ahmadieh}, {Tarek Y.} and Aoun, {Salah G.} and Daou, {Marc R.} and {El Tecle}, {Najib E.} and Rahme, {Rudy J.} and Graham, {Randall B.} and Adel, {Joseph G.} and {Hunt Batjer}, H. and Bendok, {Bernard R.}",
year = "2013",
month = "10",
doi = "10.1016/j.jocn.2013.05.009",
language = "English (US)",
volume = "20",
pages = "1350--1356",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "10",

}

TY - JOUR

T1 - New-generation oral anticoagulants for the prevention of stroke

T2 - Implications for neurosurgery

AU - El Ahmadieh, Tarek Y.

AU - Aoun, Salah G.

AU - Daou, Marc R.

AU - El Tecle, Najib E.

AU - Rahme, Rudy J.

AU - Graham, Randall B.

AU - Adel, Joseph G.

AU - Hunt Batjer, H.

AU - Bendok, Bernard R.

PY - 2013/10

Y1 - 2013/10

N2 - A new generation of oral anticoagulants, namely direct thrombin inhibitors and factor Xa inhibitors, have recently been approved for clinical use in patients with atrial fibrillation. These novel families of drugs have been shown to have favorable efficacy and safety profiles in multiple clinical settings, particularly in the prevention of atrial fibrillation-related stroke, and are likely to become part of everyday practice, making a crossover to neurosurgical patients inevitable. Concern has risen regarding the complexity of managing intracranial and intraspinal hemorrhages related to these drugs. This review aims to provide an update on the most recent advances in oral anticoagulant drug therapy from a neurosurgeon's perspective. We discuss current evidence for the use of these novel agents, their limitations, existing methods of drug-level monitoring, and controversies related to anticoagulation reversal. We also discuss specific topics such as anticoagulation resumption after intracranial or intraspinal bleeding, perioperative anticoagulant administration, and the possibility of combination with tissue plasminogen activator in the setting of acute ischemic stroke. A special focus is given to the incidence of intracranial and intraspinal hemorrhage associated with each drug.

AB - A new generation of oral anticoagulants, namely direct thrombin inhibitors and factor Xa inhibitors, have recently been approved for clinical use in patients with atrial fibrillation. These novel families of drugs have been shown to have favorable efficacy and safety profiles in multiple clinical settings, particularly in the prevention of atrial fibrillation-related stroke, and are likely to become part of everyday practice, making a crossover to neurosurgical patients inevitable. Concern has risen regarding the complexity of managing intracranial and intraspinal hemorrhages related to these drugs. This review aims to provide an update on the most recent advances in oral anticoagulant drug therapy from a neurosurgeon's perspective. We discuss current evidence for the use of these novel agents, their limitations, existing methods of drug-level monitoring, and controversies related to anticoagulation reversal. We also discuss specific topics such as anticoagulation resumption after intracranial or intraspinal bleeding, perioperative anticoagulant administration, and the possibility of combination with tissue plasminogen activator in the setting of acute ischemic stroke. A special focus is given to the incidence of intracranial and intraspinal hemorrhage associated with each drug.

KW - Atrial fibrillation

KW - Dabigatran

KW - Intracranial hemorrhage

KW - Neurosurgery

KW - Oral anticoagulant

KW - Reversal

UR - http://www.scopus.com/inward/record.url?scp=84885390003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885390003&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2013.05.009

DO - 10.1016/j.jocn.2013.05.009

M3 - Article

C2 - 23835467

AN - SCOPUS:84885390003

VL - 20

SP - 1350

EP - 1356

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 10

ER -